Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHAT | P28329 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.40 |
| ▸ | PDE5A | O76074 | 1/20 | 0.40 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.40 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10323297 | 1.00 | CHAT (0.42) | CHATSMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL11652543 | 0.93 | CYSLTR2 (0.47) | CHATSMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL11652547 | 0.93 | CYSLTR2 (0.47) | CHATSMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL20604271 | 0.89 | TLR8 (0.45) | CHATSMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL20604275 | 0.89 | TLR8 (0.45) | CHATSMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL28015713 | 0.86 | PDE5A (0.38) | SMN1; SMN2LMNAHPGDCYP1A2ALDH1A1 | |
| SCHEMBL4895093 | 0.81 | ALDH1A1 (0.43) | CHATSMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL29528779 | 0.80 | CHAT (0.47) | CHATSMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL256666 | 0.80 | CHAT (0.47) | CHATSMN1; SMN2LMNAHPGDNFE2L2 | |
| SCHEMBL6568108 | 0.80 | CHAT (0.47) | CHATSMN1; SMN2LMNAHPGDNFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970112-B1 | PHENYL CARBAMATE COMPOUND AND A COMPOSITION FOR PREVENTING OR TREATING A MEMORY LOSS-RELATED DISEASE COMPRISING THE SAME | BIO PHARM SOLUTIONS CO LTD (KR) | 2025-03-12 | — | — | EP | disclosed |
| EP-2968210-B1 | PHENYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING PEDIATRIC EPILESY | BIO PHARM SOLUTIONS CO LTD (KR) | 2024-09-11 | — | — | EP | disclosed |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| CN-111419830-B | Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes | 比皮艾思药物研发有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4204395-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| CN-115996905-A | Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases | 生物药品解决方案有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-109939092-B | Phenyl carbamate compounds for use in preventing or treating pediatric epilepsy and epilepsy-related syndrome | 比皮艾思药物研发有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| CN-111419830-A | Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epilepsy-related syndromes | 比皮艾思药物研发有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-01-03 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | US | disclosed |
| WO-2012096458-A2 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012002773-A2 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005801-A1 | PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME | CPT1B, MYLK, PYGM | CHAT 496/4885SMN1; SMN2 862/4885LMNA 1083/4885 |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | MYLK, PDE3A, TNNC1 | CHAT 619/4885SMN1; SMN2 631/4885LMNA 1572/4885 |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | SNCA, MAPT, CHAT | CHAT 3/4885SMN1; SMN2 629/4885LMNA 2457/4885 |
| US-20120184762-A1 | PROCESS FOR PREPARATION OF PHENYL CARBAMATE DERIVATIVES | CPS1, BCHE, ACHE | CHAT 9/4885SMN1; SMN2 329/4885LMNA 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.